16 stories found
Neurocrine Biosciences is reportedly close to finalizing a deal to acquire Soleno Therapeutics. The potential acquisition is valued at over $2.5 billion, according to reports from the Financial Times.
The deadline for leadership in a securities fraud lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) is approaching on May 5, 2026.
Investors in Soleno Therapeutics, Inc. (SLNO) are facing a May 5, 2026, deadline to participate in a securities fraud class action lawsuit.
Highlights from Soleno Therapeutics' fourth-quarter earnings call were published, detailing the company's recent financial results.
This cluster includes news on analyst ratings, significant investment filings, regulatory compliance, proposed rights issues, and new business orders for individual companies.
Investor sentiment for Soleno Therapeutics (SLNO) remains subdued, reflecting ongoing concerns about the company's growth prospects.
Investors in Soleno Therapeutics, Inc. (SLNO) are being offered an opportunity to lead a securities fraud class action lawsuit against the company.
Kaplan Fox has alerted investors to a securities class action lawsuit against Soleno Therapeutics, Inc. (SLNO), with a deadline for participation set for May 5, 2026.
Wells Fargo has reduced its price target for Soleno Therapeutics (SLNO) from $114 to $110, citing specific reasons for the adjustment.
Soleno Therapeutics reported GAAP EPS of $0.80, beating estimates by $0.09, and revenue of $91.73 million, surpassing estimates by $3.18 million.
Soleno Therapeutics (SLNO) continues to appear attractive to investors, even with slower U.S. launch ramp projections for its products.
Investors of BlackRock TCP Capital Corp. (NASDAQ: TCPC) are reminded by Kaplan Fox to contact them before the April 6, 2026 deadline regarding a class action lawsuit and potential recovery.
Kaplan Fox has issued an alert to investors regarding a securities class action lawsuit filed against Soleno Therapeutics, Inc., with a deadline of May 5, 2026.
Soleno Therapeutics, Inc. has released its summary for the Q4 2025 earnings call.
Multiple biotech and pharmaceutical companies, including Legend Biotech, Corcept Therapeutics, and Ultragenyx, have released updates on their drug pipelines, clinical trial data, and regulatory interactions, impacting market outlook.